|
|
|
| Effect of Sakubatril Valsartan Sodium Combined with Meglumine Adenosine Cyclophosphate in the Treatment of Chronic Heart Failure and Its Influence on Cardiac Function Indicators |
| PU Dongyu, ZHANG Xiaohan |
| Zibo Central Hospital, Shandong Province, Zibo 255036, China |
|
|
|
|
Abstract Objective: To investigate the effect of Sakubatril Valsartan Sodium combined with Meglumine Adenosine Cyclophosphate in the treatment of chronic heart failure and its influence on cardiac function indexes. Method: A total of 100 patients with chronic heart failure admitted to Zibo Central Hospital from January 2018 to January 2021 were selected, they were divided into single drug group and combined drug group by applying the random number table method, with 50 cases in each group. The single drug group received Meglumine Adenosine Cyclophosphate and the combined drug group received Sakubatril Valsartan Sodium combined with Meglumine Adenosine Cyclophosphate. The cardiac function indexes, neuroendocrine factor indexes, monocyte TLR4/NF-κB signaling pathway-related indexes and vascular endothelial function indexes were compared between the two groups. Result: Before treatment, there were no significant differences in left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT) and cardiac index (CI) between the two groups (P>0.05); after treatment, CI and LVEF in both groups were higher than those before treatment, and those in combined drug group were higher than those in single drug group; LVESD, LVEDD, IVST and LVPWT were lower than those before treatment, those in combined drug group were lower than those in single drug group, the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in the levels of N-terminal brain natriuretic peptide precursor (NT-proBNP), plasma renin assay (PRA) and antidiuretic hormone (ADH) between the two groups (P>0.05); after treatment, the levels of NT-proBNP, ADH and PRA in both groups were lower than those before treatment, the levels of NT-proBNP and ADH in combined drug group were lower than those in single drug group, the differences were statistically significant (P<0.05). After treatment, there was no significant difference in PRA level between the two groups (P>0.05). Before treatment, there were no significant differences in TLR4 mRNA, NF-κB mRNA, interleukin-6 (IL-6) mRNA and tumour necrosis factor-α (TNF-ɑ) mRNA levels between the two groups (P>0.05); after treatment, TLR4 mRNA, NF-κB mRNA, IL-6 mRNA and TNF-α mRNA in both groups were lower than those before treatment, those in combined drug group were lower than those in the single drug group, the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in brachial artery flow mediated dilation (FMD), serum endothelin-1 (ET-1) and nitric oxide (NO) between the two groups (P>0.05); after treatment, FMD and NO levels in both groups were higher than those before treatment, those in combined drug group were higher than those in single drug group, ET-1 level were lower than those before treatment, that in combined drug group was lower than that in single drug group, the differences were statistically significant (P<0.05). Conclusion: The treatment of chronic heart failure with Sakubatril Valsartan Sodium combined with Meglumine Adenosine Cyclophosphate can improve the cardiac function and vascular endothelial function of patients, and inhibit the TLR4/NF-κB signaling pathway and neuroendocrine factor secretion of monocytes with significant effect.
|
|
Received: 08 September 2022
|
|
|
|
|
|
|
